ResMed Inc (FRA:RMEA)
€ 19.7 0 (0%) Market Cap: 29.38 Bil Enterprise Value: 30.24 Bil PE Ratio: 33.16 PB Ratio: 6.85 GF Score: 97/100

Resmed Inc at William Blair Growth Stock Conference Transcript

Jun 06, 2019 / 01:40PM GMT
Release Date Price: €10
Malgorzata Maria Kaczor
William Blair & Company L.L.C., Research Division - Research Analyst

All right. We're going to kick it off here. Good morning, everyone. Thank you very much for making it out today, especially after last night. For those of you guys that didn't see me yesterday or don't know me, again, my name is Margaret Kaczor. I'm the research analyst at William Blair & Company who covers ResMed. I am required to inform you that you can obtain a complete list of risks and disclosures, the potential conflicts of interest at williamblair.com. Now ResMed, for us, is a health care technology company. Most of you know they initially got their start in sleep apnea. And they remain the market leader within that market today. The company sells industry-leading products, but ResMed is a revolutionary medtech from our perspective because it's one of the few companies that's been able to not only digitize their products, but to be able to monetize that digitization, and we think that, that is something that should drive accelerated market growth, accelerated awareness. And not only within sleep

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot